NASDAQ
IRTC

iRhythm Technologies Inc

Medical Devices
Healthcare

Prices are adjusted according to historical splits.

iRhythm Technologies Inc Stock Price

Vitals

Today's Low:
$94.95
Today's High:
$100
Open Price:
$98
52W Low:
$85.74
52W High:
$160.96
Prev. Close:
$100.17
Volume:
361515

Company Statistics

Market Cap.:
$3.06 billion
Book Value:
7.328
Revenue TTM:
$452.06 million
Operating Margin TTM:
-22.16%
Gross Profit TTM:
$281.63 million
Profit Margin:
-21.95%
Return on Assets TTM:
-14.47%
Return on Equity TTM:
-42.36%

Company Profile

iRhythm Technologies Inc had its IPO on 2016-10-20 under the ticker symbol IRTC.

The company operates in the Healthcare sector and Medical Devices industry. iRhythm Technologies Inc has a staff strength of 1,793 employees.

Stock update

Shares of iRhythm Technologies Inc opened at $98 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $94.95 - $100, and closed at $96.32.

This is a -3.84% slip from the previous day's closing price.

A total volume of 361,515 shares were traded at the close of the day’s session.

In the last one week, shares of iRhythm Technologies Inc have slipped by -5.96%.

iRhythm Technologies Inc's Key Ratios

iRhythm Technologies Inc has a market cap of $3.06 billion, indicating a price to book ratio of 12.237 and a price to sales ratio of 7.3786.

In the last 12-months iRhythm Technologies Inc’s revenue was $452.06 million with a gross profit of $281.63 million and an EBITDA of $-86682000. The EBITDA ratio measures iRhythm Technologies Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, iRhythm Technologies Inc’s operating margin was -22.16% while its return on assets stood at -14.47% with a return of equity of -42.36%.

In Q2, iRhythm Technologies Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 21.6%.

iRhythm Technologies Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-3.18 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into iRhythm Technologies Inc’s profitability.

iRhythm Technologies Inc stock is trading at a EV to sales ratio of 7.5062 and a EV to EBITDA ratio of -25.4834. Its price to sales ratio in the trailing 12-months stood at 7.3786.

iRhythm Technologies Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$429.49 million
Total Liabilities
$89.41 million
Operating Cash Flow
$9.01 million
Capital Expenditure
$9.40 million
Dividend Payout Ratio
0%

iRhythm Technologies Inc ended 2024 with $429.49 million in total assets and $0 in total liabilities. Its intangible assets were valued at $429.49 million while shareholder equity stood at $223.88 million.

iRhythm Technologies Inc ended 2024 with $0 in deferred long-term liabilities, $89.41 million in other current liabilities, 30000.00 in common stock, $-579791000.00 in retained earnings and $862000.00 in goodwill. Its cash balance stood at $61.58 million and cash and short-term investments were $164.74 million. The company’s total short-term debt was $14,099,000 while long-term debt stood at $34.94 million.

iRhythm Technologies Inc’s total current assets stands at $242.14 million while long-term investments were $0 and short-term investments were $103.16 million. Its net receivables were $51.11 million compared to accounts payable of $7.15 million and inventory worth $14.48 million.

In 2024, iRhythm Technologies Inc's operating cash flow was $9.01 million while its capital expenditure stood at $9.40 million.

Comparatively, iRhythm Technologies Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$96.32
52-Week High
$160.96
52-Week Low
$85.74
Analyst Target Price
$138.11

iRhythm Technologies Inc stock is currently trading at $96.32 per share. It touched a 52-week high of $160.96 and a 52-week low of $160.96. Analysts tracking the stock have a 12-month average target price of $138.11.

Its 50-day moving average was $104.48 and 200-day moving average was $109.83 The short ratio stood at 5.97 indicating a short percent outstanding of 0%.

Around 70.6% of the company’s stock are held by insiders while 11266.9% are held by institutions.

Frequently Asked Questions About iRhythm Technologies Inc

The stock symbol (also called stock or share ticker) of iRhythm Technologies Inc is IRTC

The IPO of iRhythm Technologies Inc took place on 2016-10-20

Similar Industry Stocks (Medical Devices)

Last Price
Chg
Chg%
Nestle SA (NSRGF)
$117.32
-2.44
-2.04%
$135.25
-5.35
-3.81%
$335.3
-5.9
-1.73%
Carysil Ltd (CARYSIL)
$638.5
-42.6
-6.25%
$32.09
0.62
+1.97%
Nutanix Inc (NTNX)
$36.22
-0.25
-0.7%
$20.84
-1.26
-5.7%
$3.5
-0.02
-0.57%
$56.58
-2.36
-4%
$33.26
-0.27
-0.81%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company’s Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient’s heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Address

699 8th Street, San Francisco, CA, United States, 94103